Brookline Capital Management Estimates UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja expects that the company will earn ($0.15) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.14 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

Separately, HC Wainwright upped their target price on shares of Unicycive Therapeutics from $4.00 to $7.50 and gave the stock a “buy” rating in a research report on Tuesday.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $0.55 on Thursday. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.60. The company has a 50-day simple moving average of $0.58 and a 200-day simple moving average of $0.57. The firm has a market capitalization of $56.93 million, a P/E ratio of -0.57 and a beta of 2.26.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UNCY. Walleye Capital LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter valued at about $2,040,000. Virtu Financial LLC boosted its holdings in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after acquiring an additional 62,881 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Unicycive Therapeutics during the third quarter valued at approximately $29,000. Northern Trust Corp increased its stake in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after acquiring an additional 34,183 shares during the period. Finally, Octagon Capital Advisors LP raised its holdings in Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after purchasing an additional 1,441,000 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.